Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Farzaneh Dastan and Payam Tabarsi.
Farzaneh Dastan
Connection Strength
6.235
Payam Tabarsi
  1. IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients. Int Immunopharmacol. 2021 Oct; 99:107998.
    View in: PubMed
    Score: 0.958
  2. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021 Jan; 90:107205.
    View in: PubMed
    Score: 0.913
  3. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol. 2020 Nov; 88:106869.
    View in: PubMed
    Score: 0.896
  4. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug; 85:106688.
    View in: PubMed
    Score: 0.886
  5. Tocilizumab administration in a refractory case of COVID-19. Int J Antimicrob Agents. 2020 Aug; 56(2):106043.
    View in: PubMed
    Score: 0.885
  6. Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial. Int Immunopharmacol. 2021 Oct; 99:108043.
    View in: PubMed
    Score: 0.240
  7. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021 Apr 15; 897:173947.
    View in: PubMed
    Score: 0.232
  8. Combination therapy of IFNß1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. Int Immunopharmacol. 2021 Mar; 92:107329.
    View in: PubMed
    Score: 0.230
  9. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. Int Immunopharmacol. 2020 Dec; 89(Pt B):107102.
    View in: PubMed
    Score: 0.227
  10. Extracorporeal membrane oxygenation and COVID-19: The causes of failure. J Card Surg. 2020 Oct; 35(10):2838-2843.
    View in: PubMed
    Score: 0.223
  11. Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. Iran J Pharm Res. 2020; 19(1):1-2.
    View in: PubMed
    Score: 0.215
  12. Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients. Tanaffos. 2020 Dec; 19(4):291-299.
    View in: PubMed
    Score: 0.057
  13. NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. Tanaffos. 2020 Nov; 19(2):91-99.
    View in: PubMed
    Score: 0.057
  14. Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. Tanaffos. 2020 Nov; 19(2):112-121.
    View in: PubMed
    Score: 0.057
  15. Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. Tanaffos. 2020 Nov; 19(2):122-128.
    View in: PubMed
    Score: 0.057
  16. A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. Iran J Pharm Res. 2020; 19(1):31-36.
    View in: PubMed
    Score: 0.054
  17. Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital. Tanaffos. 2018 Mar; 17(3):183-187.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.